TransCode Therapeutics shares are trading higher after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics announced positive pre-clinical gliblastoma results with its lead candidate, TTX-MC138, leading to a rise in its share prices.
September 25, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransCode Therapeutics' positive pre-clinical results for TTX-MC138 have led to an increase in its share prices.
The announcement of positive pre-clinical results for TransCode Therapeutics' lead candidate, TTX-MC138, has led to a surge in the company's share prices. This indicates a positive market response to the news, which could potentially lead to further increases in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100